Published in Science on September 08, 2010
Cancer genome landscapes. Science (2013) 25.33
Signatures of mutational processes in human cancer. Nature (2013) 21.63
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Initial impact of the sequencing of the human genome. Nature (2011) 9.18
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res (2011) 4.91
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet (2014) 3.75
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 3.51
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Epigenetic reprogramming in cancer. Science (2013) 3.47
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med (2015) 2.88
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med (2014) 2.69
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest (2012) 2.42
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med (2015) 2.41
Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet (2011) 2.38
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med (2012) 2.06
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol (2011) 2.03
The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One (2013) 2.00
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A (2012) 1.90
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov (2012) 1.81
Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett (2013) 1.74
Type-specific cell line models for type-specific ovarian cancer research. PLoS One (2013) 1.73
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol (2011) 1.60
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014) 1.56
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas. PLoS One (2015) 1.44
Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci (2010) 1.44
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol (2012) 1.41
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun (2015) 1.35
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv (2015) 1.33
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene (2011) 1.33
Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene (2013) 1.33
Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer (2012) 1.32
The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. Hum Genet (2013) 1.27
Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer (2012) 1.26
SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse functions. J Biol Chem (2012) 1.24
Ovarian Cancer Is an Imported Disease: Fact or Fiction? Curr Obstet Gynecol Rep (2012) 1.23
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia (2012) 1.22
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev (2013) 1.22
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab (2012) 1.21
Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene (2012) 1.21
The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther (2014) 1.21
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell (2014) 1.20
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch (2011) 1.19
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia (2013) 1.17
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer (2012) 1.14
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst (2014) 1.14
TCR-dependent transformation of mature memory phenotype T cells in mice. J Clin Invest (2011) 1.13
Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One (2012) 1.12
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med (2015) 1.10
Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet (2014) 1.10
The genetic landscape of anaplastic astrocytoma. Oncotarget (2014) 1.09
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
The epigenomics of cancer. Cell (2007) 30.91
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Serine/threonine phosphatases: mechanism through structure. Cell (2009) 6.19
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
PP2A is required for centromeric localization of Sgo1 and proper chromosome segregation. Dev Cell (2006) 3.88
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Understanding the words of chromatin regulation. Cell (2009) 3.67
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J (2007) 2.75
Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology (1997) 2.60
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer (2007) 1.99
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71
SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res (2005) 1.68
Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol (2001) 1.52
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
International network of cancer genome projects. Nature (2010) 20.35
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The antisense transcriptomes of human cells. Science (2008) 6.29
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29